Camrelizumab in Combination With Apatinib in Advanced ICC: A Single-arm Phase II Study
Last updated on July 2021Recruitment
- Recruitment Status
- Not yet recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Intrahepatic Cholangiocarcinoma
- Type
- Interventional
- Phase
- Phase 2
- Design
- Allocation: N/AIntervention Model: Single Group AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 70 years
- Gender
- Both males and females
Description
It is estimated that 50 patients who met the study criteria will be enrolled in 1 years and treated with Camrelizumab plus Apatinib in SYSUCC. The investigators will follow up and collect subjects' data to evaluate the efficacy and safety of treatment, including objective response rate (ORR) and Pro...
It is estimated that 50 patients who met the study criteria will be enrolled in 1 years and treated with Camrelizumab plus Apatinib in SYSUCC. The investigators will follow up and collect subjects' data to evaluate the efficacy and safety of treatment, including objective response rate (ORR) and Progression-free Survival (PFS) and Overall Survival (OS), until disease progression or death. Histopathology and multi-omics data analysis will be used to explore potential biomarkers of treatment response.
Tracking Information
- NCT #
- NCT04454905
- Collaborators
- Jiangsu HengRui Medicine Co., Ltd.
- Investigators
- Not Provided
Get Well Soon